Life–changing therapy by global leaders in ophthalmology
Eyerising International is an Australian MedTech company developing life-impacting eye-health therapy to slow the progression of myopia. We are led by a team of world-renowned ophthalmology academics, researchers and a board with a proven track record in MedTech innovation, implementation, and clinical facilitation.
Patented childhood myopia control therapy
Eyerising International’s Myopia Management Repeated Low-Level Red–Light (RLRL) therapy was conceived and developed by ERI’s Chief Medical Officer, Professor Mingguang He, a global leader in myopia control and the development of artificial intelligence systems in ophthalmology. This innovation in childhood myopia control meets the quality, safety, and efficacy standards required by medical regulators in over 30 countries across Europe and Australasia.